From the smallest biotech to the biggest pharmaceutical stock, The Motley Fool's Market Check-Up covers the health-care sector's biggest headlines, hottest market movers, and Obamacare's ongoing rollout.
In this segment, health-care analyst David Williamson discusses Merck's latest anti-viral successes. The company now has a new HPV vaccine that offers protection not only against the four strains that the company's previous vaccine covers against, but also against five additional strains. David also says he likes Merck's hepatitis C drug combo, currently in phase 2 trials, even though it may be a bit late to the game in this space. David tells investors what he likes about these two developments but also discusses why he isn't excited about these drugs just yet.
Getting a handle on cancer
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.
The article Merck's Exciting Anti-Virus Pipeline originally appeared on Fool.com.Alison Southwick has no position in any stocks mentioned. David Williamson owns shares of Merck and AbbVie. Follow David on Twitter: @MotleyDavid. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.